Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Biol Chem
2019 Aug 23;29434:12766-12778. doi: 10.1074/jbc.RA119.009464.
Show Gene links
Show Anatomy links
Phosphomimetic substitution at Ser-33 of the chloroquine resistance transporter PfCRT reconstitutes drug responses in Plasmodium falciparum.
Sanchez CP
,
Moliner Cubel S
,
Nyboer B
,
Jankowska-Döllken M
,
Schaeffer-Reiss C
,
Ayoub D
,
Planelles G
,
Lanzer M
.
???displayArticle.abstract???
The chloroquine resistance transporter PfCRT of the human malaria parasite Plasmodium falciparum confers resistance to the former first-line antimalarial drug chloroquine, and it modulates the responsiveness to a wide range of quinoline and quinoline-like compounds. PfCRT is post-translationally modified by phosphorylation, palmitoylation, and, possibly, ubiquitination. However, the impact of these post-translational modifications on P. falciparum biology and, in particular, the drug resistance-conferring activity of PfCRT has remained elusive. Here, we confirm phosphorylation at Ser-33 and Ser-411 of PfCRT of the chloroquine-resistant P. falciparum strain Dd2 and show that kinase inhibitors can sensitize drug responsiveness. Using CRISPR/Cas9 genome editing to generate genetically engineered PfCRT variants in the parasite, we further show that substituting Ser-33 with alanine reduced chloroquine and quinine resistance by ∼50% compared with the parental P. falciparum strain Dd2, whereas the phosphomimetic amino acid aspartic acid could fully and glutamic acid could partially reconstitute the level of chloroquine/quinine resistance. Transport studies conducted in the parasite and in PfCRT-expressing Xenopus laevis oocytes linked phosphomimetic substitution at Ser-33 to increased transport velocity. Our data are consistent with phosphorylation of Ser-33 relieving an autoinhibitory intramolecular interaction within PfCRT, leading to a stimulated drug transport activity. Our findings shed additional light on the function of PfCRT and suggest that chloroquine could be reevaluated as an antimalarial drug by targeting the kinase in P. falciparum that phosphorylates Ser-33 of PfCRT.
Agrawal,
Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity.
2017, Pubmed
Agrawal,
Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity.
2017,
Pubmed
Antony,
In silico modeling of Plasmodium falciparum chloroquine resistance transporter protein and biochemical studies suggest its key contribution to chloroquine resistance.
2019,
Pubmed
Aryal,
Learning from each other: ABC transporter regulation by protein phosphorylation in plant and mammalian systems.
2015,
Pubmed
Bain,
The specificities of protein kinase inhibitors: an update.
2003,
Pubmed
Bakouh,
Iron is a substrate of the Plasmodium falciparum chloroquine resistance transporter PfCRT in Xenopus oocytes.
2017,
Pubmed
,
Xenbase
Bellanca,
Multiple drugs compete for transport via the Plasmodium falciparum chloroquine resistance transporter at distinct but interdependent sites.
2014,
Pubmed
,
Xenbase
Ciarimboli,
Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation.
2005,
Pubmed
Coronado,
Malarial hemozoin: from target to tool.
2014,
Pubmed
Davies,
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
2000,
Pubmed
Dhingra,
A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine.
2017,
Pubmed
Dounay,
Okadaic acid: the archetypal serine/threonine protein phosphatase inhibitor.
2002,
Pubmed
Egan,
Interactions of quinoline antimalarials with hematin in solution.
2006,
Pubmed
Fidock,
Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance.
2000,
Pubmed
Gabryszewski,
Combinatorial Genetic Modeling of pfcrt-Mediated Drug Resistance Evolution in Plasmodium falciparum.
2016,
Pubmed
Ghorbal,
Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system.
2014,
Pubmed
Heinberg,
The molecular basis of antifolate resistance in Plasmodium falciparum: looking beyond point mutations.
2015,
Pubmed
Ho,
Site-directed mutagenesis by overlap extension using the polymerase chain reaction.
1989,
Pubmed
Holland,
Functional analysis of protein kinase CK2 of the human malaria parasite Plasmodium falciparum.
2009,
Pubmed
Johnson,
Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents.
2004,
Pubmed
Jones,
Analysis of protein palmitoylation reveals a pervasive role in Plasmodium development and pathogenesis.
2012,
Pubmed
Juge,
Plasmodium falciparum chloroquine resistance transporter is a H+-coupled polyspecific nutrient and drug exporter.
2015,
Pubmed
Kuhn,
Trafficking of the phosphoprotein PfCRT to the digestive vacuolar membrane in Plasmodium falciparum.
2010,
Pubmed
Lakshmanan,
A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance.
2005,
Pubmed
Lambros,
Synchronization of Plasmodium falciparum erythrocytic stages in culture.
1979,
Pubmed
Lasonder,
The Plasmodium falciparum schizont phosphoproteome reveals extensive phosphatidylinositol and cAMP-protein kinase A signaling.
2012,
Pubmed
Lin-Moshier,
A rapid Western blotting protocol for the Xenopus oocyte.
2013,
Pubmed
,
Xenbase
Lucet,
Plasmodium kinases as targets for new-generation antimalarials.
2012,
Pubmed
Martin,
The malaria parasite's chloroquine resistance transporter is a member of the drug/metabolite transporter superfamily.
2004,
Pubmed
Martin,
Chloroquine transport via the malaria parasite's chloroquine resistance transporter.
2009,
Pubmed
,
Xenbase
Mehrens,
The affinity of the organic cation transporter rOCT1 is increased by protein kinase C-dependent phosphorylation.
2000,
Pubmed
Moritz,
Reciprocal Phosphorylation and Palmitoylation Control Dopamine Transporter Kinetics.
2015,
Pubmed
Patzewitz,
Glutathione transport: a new role for PfCRT in chloroquine resistance.
2013,
Pubmed
,
Xenbase
Petersen,
Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter.
2015,
Pubmed
Saitoh,
Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase.
1987,
Pubmed
Sanchez,
Trans stimulation provides evidence for a drug efflux carrier as the mechanism of chloroquine resistance in Plasmodium falciparum.
2003,
Pubmed
Sanchez,
Evidence for a substrate specific and inhibitable drug efflux system in chloroquine resistant Plasmodium falciparum strains.
2004,
Pubmed
Sanchez,
Differences in trans-stimulated chloroquine efflux kinetics are linked to PfCRT in Plasmodium falciparum.
2007,
Pubmed
Sanchez,
Genetic linkage analyses redefine the roles of PfCRT and PfMDR1 in drug accumulation and susceptibility in Plasmodium falciparum.
2011,
Pubmed
Sanchez,
A HECT ubiquitin-protein ligase as a novel candidate gene for altered quinine and quinidine responses in Plasmodium falciparum.
2014,
Pubmed
Sardet,
Alpha-thrombin, epidermal growth factor, and okadaic acid activate the Na+/H+ exchanger, NHE-1, by phosphorylating a set of common sites.
1991,
Pubmed
Sidhu,
Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations.
2002,
Pubmed
Smilkstein,
Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening.
2004,
Pubmed
Solyakov,
Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum.
2011,
Pubmed
Summers,
Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics.
2012,
Pubmed
Summers,
Diverse mutational pathways converge on saturable chloroquine transport via the malaria parasite's chloroquine resistance transporter.
2014,
Pubmed
,
Xenbase
Sá,
Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine.
2009,
Pubmed
Trager,
Human malaria parasites in continuous culture.
1976,
Pubmed
Tran,
The principal chloroquine resistance protein of Plasmodium falciparum is a member of the drug/metabolite transporter superfamily.
2004,
Pubmed
Umeda,
H89 (N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide) induces reduction of myosin regulatory light chain phosphorylation and inhibits cell proliferation.
2008,
Pubmed
Wu,
Transfection of Plasmodium falciparum within human red blood cells.
1995,
Pubmed
Yamaki,
[Platelet cyclic nucleotides and calcium].
1979,
Pubmed
Yuan,
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
2011,
Pubmed
Zimmer,
Calmodulin activates bovine-cardiac myosin light-chain kinase by increasing the affinity for myosin light-chain 2.
1984,
Pubmed
van Schalkwyk,
Verapamil-Sensitive Transport of Quinacrine and Methylene Blue via the Plasmodium falciparum Chloroquine Resistance Transporter Reduces the Parasite's Susceptibility to these Tricyclic Drugs.
2016,
Pubmed
,
Xenbase
